The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

Background The duration and effectiveness of immunity from infection with and vaccination
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At …

Although infections among vaccinated individuals lead to milder COVID-19 symptoms
relative to those in unvaccinated subjects, the specificity and durability of antibody …

Background The duration of protection against the omicron (B. 1.1. 529) variant for current
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially …

Background Strategies to control coronavirus 2019 disease (COVID-19) have often been
based on preliminary and limited data and have tended to be slow to evolve as new …

The durability of vaccine-mediated immunity to SARS-CoV-2, the durations to breakthrough
infection, and the optimal timings of booster vaccination are crucial knowledge for pandemic …

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly
understood. A range of sociodemographic, behavioural, clinical, pharmacologic and …

Background Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly
recommended, but immunogenicity data remain limited, particularly in older adults. Methods …